China Detains AstraZeneca (AZN) Staff in Data, Drug-import Probes - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN), PT $91.70, 'TL-01 final OS underwhelms', Shares down ~2.3%
September 9, 2024 3:07 PM EDTBofA Securities analyst Sachin Jain reiterated a Buy rating and $91.70 price target on AstraZeneca (NASDAQ: AZN).
The analyst comments "TL01 final OS underwhelming, puts TL01 approval at risk AZN presented final OS data for datopotamab from TL01 2L lung cancer study at World Lung,... More
AstraZeneca (AZN) Shares Down 3%+ Following Update
September 9, 2024 2:03 PM EDTAstraZeneca (NASDAQ: AZN) Shares Decline 3% Following Update.
At 2:50pm Eastern Time the company reported datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial.
... More
AstraZeneca (AZN) Shares Down ~2.5% Following Update
September 9, 2024 1:58 PM EDTAstraZeneca (NASDAQ: AZN) Shares Down 2.5% Following Update.
At 2:50pm Eastern Time the company reported datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial.
... More
